|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||135.61 - 138.62|
|52 Week Range||103.00 - 149.07|
|Beta (3Y Monthly)||1.21|
|PE Ratio (TTM)||29.17|
|Earnings Date||Jul 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||149.46|
Charles River Laboratories International, Inc. will release second-quarter 2019 financial results on Wednesday, July 31st, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, July 31st, at 8:30 a.m.
Charles River Laboratories International, Inc. (CRL) today announced the planned opening of the Charles River Accelerator and Development Lab (CRADL™) in South San Francisco in early 2020. CRADL provides flexible, turnkey vivarium rental space supported by Charles River’s technical, vivarium, and veterinary support expertise in key biohubs. CRADL is the leading space for clients to launch or expand their drug research programs, with the added benefit of access to Charles River’s complete portfolio of integrated drug discovery resources.
Does Charles River Laboratories International Inc. (NYSE:CRL) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why […]
During the Lightning Round of Mad Money Thursday night, Jim Cramer mentioned to one caller that he also likes Charles River Laboratories International Inc. In the daily bar chart of CRL, below, we can see some bearish signals. The On-Balance-Volume (OBV) line shows weakness from late April telling us that sellers of CRL have become more aggressive.
Charles River Laboratories International Inc NYSE:CRLView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CRL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CRL. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CRL totaled $7 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Charles River Laboratories International, Inc. announced today that it will present at two upcoming investor conferences, including:
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Charles River earnings of $1.40 a share, on an adjusted basis, on $604.6 million in sales beat first-quarter estimates Tuesday. But shares closed down on worries of a China trade war.
Charles River (CRL) delivered earnings and revenue surprises of 1.45% and 0.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Wilmington, Massachusetts-based company said it had profit of $1.11 per share. Earnings, adjusted for non-recurring costs, came to $1.40 per share. The results surpassed Wall Street expectations. The ...
Pomerantz LLP is investigating claims on behalf of investors of Charles River Laboratories International, Inc. (“Charles River” or the “Company”) (NYSE: CRL). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. On April 30, 2019, Charles River disclosed that a “highly sophisticated, well-resourced intruder” accessed its information system in mid-March 2019, and that data belonging to “approximately 1% of Charles River’s total number of clients” was “known to have been copied”. Following this disclosure, Charles River’s stock price fell $5.11 per share, or 3.59%, over the following two trading sessions, closing at $137.41 per share on May 1, 2019. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.
An unidentified group of hackers recently broke into Charles River Laboratories’ information system and copied some drug developers’ data, the company disclosed Tuesday.
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Laboratories International, Inc. (CRL) announced today that it has completed the previously announced acquisition of Citoxlab for €448 million in cash (or approximately $500 million based on current exchange rates), subject to customary closing adjustments. Citoxlab is a premier, non-clinical contract research organization (CRO), specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing. With operations in Europe and North America, the acquisition of Citoxlab will further strengthen Charles River’s position as the leading, global, early-stage CRO by expanding its scientific portfolio and geographic footprint, which will enhance the Company’s ability to partner with clients across the drug discovery and development continuum.
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E ratio and reflect on what it tells us about the...
Teladoc (TDOC) teams up with Cincinnati Children's Hospital Medical Center to launch consumer pediatric telehealth platform.